<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02837445</url>
  </required_header>
  <id_info>
    <org_study_id>CS-03 Ver 1.1</org_study_id>
    <nct_id>NCT02837445</nct_id>
  </id_info>
  <brief_title>Moderato System: A Double-Blind Randomized Trial Ver 1.1</brief_title>
  <official_title>Clinical Evaluation of Safety and Effectiveness of the BackBeat Medical Moderato System in Patients With Hypertension: A Double-Blind Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BackBeat Medical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MLM Medical Labs GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>nabios GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BackBeat Medical Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this double blind randomized study is the evaluation of the safety and&#xD;
      efficacy of the Moderato System.&#xD;
&#xD;
      The Moderato implantable pulse generator is indicated for patients who have hypertension and&#xD;
      also require a dual chamber pacemaker in order to reduce their blood pressure.&#xD;
&#xD;
      The primary objectives of this study are to provide evidence of safety and clinical efficacy&#xD;
      of the anti-hypertensive effects of the Moderato System. This will be accomplished by&#xD;
      evaluating changes in blood pressure in an active treatment vs. a control patient population&#xD;
      for a period of 6 months.&#xD;
&#xD;
      The device will be considered to have a clinical effectiveness with regard to its&#xD;
      anti-hypertension functions if there is a statistically significant and clinically meaningful&#xD;
      reduction in mean 24-hour ambulatory systolic blood pressure in the treatment group compared&#xD;
      to the control group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol CS-03 Ver 1.1 (NCT02837445) was amended at the advice of the Scientific Advisory to&#xD;
      protocol CS-03 Version 3.0 with more stringent hypertension inclusion criteria and different&#xD;
      observation intervals for efficacy and safety.&#xD;
&#xD;
      In CS-03 Version 3.0 the time of the primary efficacy endpoint was reduced from 6 months to 3&#xD;
      months post randomization which was deemed a suitable interval for the chronic effect,&#xD;
      whereas for the safety endpoint, the period was lengthened from 6 month to 12 months post&#xD;
      randomization to better monitor potential risks of the treatment on cardiac function&#xD;
      (Blinding period was increased from 6 to 12 months). Protocols were thus split in order to&#xD;
      allow better clarification to the difference in the time to the primary endpoints for&#xD;
      efficacy and safety between the two CIP versions and simplify data analysis.&#xD;
&#xD;
      Protocol Ver 3.0 prescribes data analysis of all patients randomized under version 1.1 to be&#xD;
      performed once they complete the 6 months follow-up as set in protocol version 1.1&#xD;
      (NCT0283744). It is expected that ~40 patients will be randomized according to protocol&#xD;
      version 1.1 prior to the enrollment of patients according to protocol version 3.0. The&#xD;
      results will be considered as interim analysis.&#xD;
&#xD;
      The recruitment for the protocol version 1.1 is now completed. Total of 47 patients were&#xD;
      randomized according to protocol version 1.1 and all patients completed the follow-up period&#xD;
      for the primary endpoint.&#xD;
&#xD;
      Patients are currently being followed up for the study &quot;extension period&quot;.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 12, 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">August 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of composite of major cardiac events</measure>
    <time_frame>6 months post Randomization</time_frame>
    <description>including heart failure, clinically significant arrhythmias eg, persistent or increased atrial fibrillation, serious ventricular arrhythmias, myocardial infarction, stroke, heart failure, renal failure and/or related safety events that result in death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in average 24 hour systolic ambulatory blood pressure</measure>
    <time_frame>Week 3 pre Randomization and 6 months post Randomization</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Hypertension Resistant to Conventional Therapy</condition>
  <condition>Bradycardia</condition>
  <condition>Atrioventricular Block</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible patients randomized after optimization phase to PHC ON for 6 months Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible patients randomized after optimization phase to pacemaker only (PHC OFF) for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PHC ON</intervention_name>
    <description>Eligible patients randomized after optimization phase to PHC ON for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PHC OFF</intervention_name>
    <description>Eligible patients randomized after optimization phase to PHC OFF for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject requires an implant or replacement a of dual chamber pacemaker&#xD;
&#xD;
          -  Stable (at least one month) hypertension treatment with at least 1 anti-hypertensive&#xD;
             drug, which is anticipated to be maintained for 7 months.&#xD;
&#xD;
          -  Average day time (7AM-10PM) ambulatory systolic blood pressure ≥ 130 mmHg and office&#xD;
             blood pressure ≥140 mmHg.&#xD;
&#xD;
          -  Subject lives in the proximity of the study center, which permits compliance with&#xD;
             study visits for at least 7 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known secondary cause of HTN.&#xD;
&#xD;
          -  Average ambulatory or office systolic BP &gt; 195 mmHg.&#xD;
&#xD;
          -  Permanent atrial fibrillation.&#xD;
&#xD;
          -  History of significant paroxysmal atrial fibrillation/flutter burden (defined as &gt;25%&#xD;
             of beats).&#xD;
&#xD;
          -  Cardiac ejection fraction &lt;50%.&#xD;
&#xD;
          -  Symptoms of heart failure, NYHA Class II or greater.&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy, restrictive cardiomyopathy or inter-ventricular septal&#xD;
             thickness ≥ 15 mm.&#xD;
&#xD;
          -  Subject is on dialysis.&#xD;
&#xD;
          -  Subject has an estimated Glomerular Filtration Rate &lt; 30 ml/min/1.73 m²&#xD;
&#xD;
          -  Prior neurological events (stroke or TIA) within the past year or events at a prior&#xD;
             time that has resulted in residual neurologic deficit.&#xD;
&#xD;
          -  Carotid artery disease.&#xD;
&#xD;
          -  Known autonomic dysfunction.&#xD;
&#xD;
          -  History of clinically significant untreated ventricular tachyarrhythmia or has&#xD;
             experienced sudden death.&#xD;
&#xD;
          -  Previous active device-based treatment for HTN.&#xD;
&#xD;
          -  Existing implant, other than a pacemaker that needs replacing.&#xD;
&#xD;
          -  Subject is or has the possibility of becoming pregnant and is unwilling of&#xD;
             contraception during the study.&#xD;
&#xD;
          -  Subject is unwilling or cannot provide Informed Consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl-Heinz Kuck, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asklepios Klinik St. Georg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel - Heart Rhythm Management Center</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <zip>15030</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University Heart and Vascular Center</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P. Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santariskiu Klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Gdansk</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Przemiemienia Panskiego</name>
      <address>
        <city>Poznań</city>
        <zip>61-848</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pomeranian Medical University Hospital no. 2</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielnym Publicznym Centralnym Szpitalem Klinicznym</name>
      <address>
        <city>Warsaw</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silesian Center for Heart Diseases</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 8, 2016</study_first_submitted>
  <study_first_submitted_qc>July 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2016</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Bradycardia</mesh_term>
    <mesh_term>Atrioventricular Block</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

